Skip to main content

Table 1 Vaccine-related inputs for the probabilistic base-case and sensitivity analyses

From: Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada

Category/input

Base case [source]

Rangea [source]; SE

First-dose coverageb %

60 [assumed]

50–80 [assumed]; NA

Second-dose compliancec %

100 [assumed]

85 [48] to 100 [assumed]; NA

Initial RZV efficacy against HZ (2 doses)d %

72.5 [24]

58.3–82.4 [24]; 6.13

Initial RZV efficacy against HZ (1 dose), %

58.02 [80% of 2-dose efficacy]e

46.42–69.63 [± 20%]; 5.92

Initial RZV efficacy against PHN (2 doses)f %

94.82 [derived from data on file]

58.33–100 [derived from data on file]; 10.63

Initial RZV efficacy against PHN (1 dose), %

75.86 [80% of 2-dose efficacy]e

60.69–91.03 [± 20%]; 7.74

Annual waning of RZV efficacy (2 doses)f,g %

9.10 [estimated from data on file]

4.55 [–50%] to 18.20 [+ 100%]; 3.48

Annual waning of RZV efficacy (1 dose)g %

18.20 [200% of 2-dose waning]e

9.10–27.30 [± 50%]; 4.64

Incidence of AEs per RZV dose for ages 18–49 and ≥ 50 years, respectivelyf

 Local/general

0.845 and 0.827 [data on file]

Not varied

 Primary care provider

0.0203 and 0.017 [data on file]

Not varied

 Emergency room

0.0045 and 0 [data on file]

Not varied

 Hospitalization

0.0045 and 0.0022 [data on file]

Not varied

  1. AE adverse event, CI confidence interval, HZ herpes zoster, IC immunocompromised, NA not applicable, PHN postherpetic neuralgia, RZV recombinant zoster vaccine, SE standard error
  2. aFor the probabilistic base-case analysis, the uniform distribution was used for first-dose coverage and second-dose compliance; the beta distribution was assumed for all efficacy and waning-related inputs. The SEs applied in the beta distribution parameters were consistent with the reported ranges representing 95% CIs
  3. bBase case was assumed to be higher than the 44% influenza vaccination coverage for adults aged 18–64 years with a chronic medical condition from [46]; lower bound was assumed to be 50% based on the coverage for pneumonia vaccine among people aged ≥ 65 years in Canada [49]; upper bound was assumed to be 80% to reflect national coverage goals for influenza vaccination [46]
  4. cBase case was assumed to be 100% based on the assumption used in [47] and 81% completion of 4-dose HZ vaccine in [48]
  5. dYear 1 RZV efficacy (95% CI) [data on file] was taken from the study reported in [14], as used by [24]
  6. eLimited data were available to estimate efficacy and waning for 1-dose RZV due to high second-dose completion rates in [14]. Therefore, the efficacy of 1-dose RZV was assumed to be 80% that of 2-dose RZV, and annual waning of efficacy for 1-dose RZV was assumed to be 200% that of 2-dose RZV
  7. fFrom [data on file] of the study reported in [14]
  8. gThese inputs apply to individuals with IC status only. Values for individuals with healthy status are detailed in Supplemental Table 6
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us